ScinoPharm Taiwan Financials
| 1789 Stock | TWD 22.70 0.25 1.09% |
ScinoPharm |
Understanding current and past ScinoPharm Taiwan Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of ScinoPharm Taiwan's financial statements are interrelated, with each one affecting the others. For example, an increase in ScinoPharm Taiwan's assets may result in an increase in income on the income statement.
Please note, the imprecision that can be found in ScinoPharm Taiwan's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of ScinoPharm Taiwan. Check ScinoPharm Taiwan's Beneish M Score to see the likelihood of ScinoPharm Taiwan's management manipulating its earnings.
ScinoPharm Taiwan Stock Summary
ScinoPharm Taiwan competes with Siward Crystal, Chung Hwa, X Legend, Asmedia Technology, and Hunya Foods. ScinoPharm Taiwan, Ltd., together with its subsidiaries, researches and develops, produces, and sells CGMP active pharmaceutical ingredients to pharmaceutical companies in Taiwan, the United States, Europe, India, rest of Asia, and internationally. ScinoPharm Taiwan, Ltd. was founded in 1997 and is headquartered in Tainan, Taiwan. SCINOPHARM TAIWAN operates under Drug Manufacturers - Specialty Generic classification in Taiwan and is traded on Taiwan Stock Exchange.| Instrument | Taiwan Stock View All |
| Exchange | Taiwan Stock Exchange |
| ISIN | TW0001789006 |
| Business Address | No 1, Nan-Ke |
| Sector | Pharmaceuticals |
| Industry | Health Care |
| Benchmark | Dow Jones Industrial |
| Website | www.scinopharm.com |
| Phone | 886 6 505 2888 |
| Currency | TWD - New Taiwan Dollar |
You should never invest in ScinoPharm Taiwan without having analyzed its financial statements. Do not rely on someone else's analysis or guesses about the future performance of ScinoPharm Stock, because this is throwing your money away. Analyzing the key information contained in ScinoPharm Taiwan's financial statements can give you an edge over other investors and help to ensure that your investments perform well for you.
ScinoPharm Taiwan Key Financial Ratios
There are many critical financial ratios that ScinoPharm Taiwan's investors are exposed to on a daily basis, but they are usually grouped into few meaningful categories from each financial statement that ScinoPharm Taiwan reports annually and quarterly.| Return On Equity | 0.0295 | |||
| Return On Asset | 0.0184 | |||
| Target Price | 27.0 | |||
| Number Of Employees | 47 | |||
| Beta | 0.42 |
ScinoPharm Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining ScinoPharm Taiwan's current stock value. Our valuation model uses many indicators to compare ScinoPharm Taiwan value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across ScinoPharm Taiwan competition to find correlations between indicators driving ScinoPharm Taiwan's intrinsic value. More Info.ScinoPharm Taiwan is number one stock in return on equity category among its peers. It also is number one stock in return on asset category among its peers reporting about 0.62 of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for ScinoPharm Taiwan is roughly 1.60 . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the ScinoPharm Taiwan's earnings, one of the primary drivers of an investment's value.ScinoPharm Taiwan Systematic Risk
ScinoPharm Taiwan's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. ScinoPharm Taiwan volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was twenty with a total number of output elements of fourty-one. The Beta measures systematic risk based on how returns on ScinoPharm Taiwan correlated with the market. If Beta is less than 0 ScinoPharm Taiwan generally moves in the opposite direction as compared to the market. If ScinoPharm Taiwan Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one ScinoPharm Taiwan is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of ScinoPharm Taiwan is generally in the same direction as the market. If Beta > 1 ScinoPharm Taiwan moves generally in the same direction as, but more than the movement of the benchmark.
ScinoPharm Taiwan March 21, 2025 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of ScinoPharm Taiwan help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of ScinoPharm Taiwan. We use our internally-developed statistical techniques to arrive at the intrinsic value of ScinoPharm Taiwan based on widely used predictive technical indicators. In general, we focus on analyzing ScinoPharm Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build ScinoPharm Taiwan's daily price indicators and compare them against related drivers.
| Downside Deviation | 0.7283 | |||
| Information Ratio | 0.152 | |||
| Maximum Drawdown | 4.24 | |||
| Value At Risk | (1.09) | |||
| Potential Upside | 1.79 |
Additional Tools for ScinoPharm Stock Analysis
When running ScinoPharm Taiwan's price analysis, check to measure ScinoPharm Taiwan's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ScinoPharm Taiwan is operating at the current time. Most of ScinoPharm Taiwan's value examination focuses on studying past and present price action to predict the probability of ScinoPharm Taiwan's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ScinoPharm Taiwan's price. Additionally, you may evaluate how the addition of ScinoPharm Taiwan to your portfolios can decrease your overall portfolio volatility.